<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04200404</url>
  </required_header>
  <id_info>
    <org_study_id>CS1001/Regorafenib-101</org_study_id>
    <nct_id>NCT04200404</nct_id>
  </id_info>
  <brief_title>A Study of CS1001 in Subjects With Advanced or Refractory Solid Tumors</brief_title>
  <official_title>A Phase Ib/II, Multicenter Open-label Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CStone Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CStone Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment
      effect of CS1001 in combination with regorafenib in patients with advanced or refractory
      cancers
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 13, 2019</start_date>
  <completion_date type="Anticipated">July 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>From the day of first dose to 90 days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Limiting Toxicity (DLT)</measure>
    <time_frame>First cycle (28 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>To be performed every 8 weeks during treatment period (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>From the day of first dose to 30 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>From the day of first dose to 30 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum plasma concentration (Tmax)</measure>
    <time_frame>From the day of first dose to 30 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (t1/2)</measure>
    <time_frame>From the day of first dose to 30 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-CS1001 antibody</measure>
    <time_frame>From the day of first dose to 30 days after last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">138</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>CS1001+Regorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the dose escalation part, the dose levels will be escalated following a BOIN design. In the dose expansion part, patients will be assigned to different groups based on their tumor types and treated at the RP2D.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS1001</intervention_name>
    <description>CS1001 will be administrated by intravenous (i.v.) infusion once every 28 days</description>
    <arm_group_label>CS1001+Regorafenib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib</intervention_name>
    <description>The starting dose of regorafenib is 80 mg orally, once daily for the first 21 days of each 28-day cycle.</description>
    <arm_group_label>CS1001+Regorafenib</arm_group_label>
    <other_name>BAY 73-4506</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All participants must have unresectable advanced or metastatic tumors that have
             histologic or cytologic documentation confirmed.

          -  Participant must have at least one measurable lesion by CT or MRI per RECIST 1.1;
             radiographic tumor assessment should be performed within 28 days prior to initiation
             of study treatment.

          -  ECOG performance status score of 0 or 1.

          -  Life expectancy â‰¥ 12 weeks.

          -  Fresh or archival tumor tissue must be provided for PD-L1 expression testing.

          -  Adequate organ function

          -  Women of childbearing potential (WOCBP) must have a negative serum pregnancy test
             result. Either Female or male participants must agree to use adequate contraceptive
             measures from signing informed consent and for 180 days after last investigational
             product administration, except for a participant with documented surgical
             sterilization or a postmenopausal female.

        Exclusion Criteria:

          -  Prior malignancy active within the previous 3 years except for locally curable cancers
             that have been apparently cured.

          -  Participants with any condition that impairs their ability to take oral medication,
             such as lack of physical integrity of the upper gastrointestinal tract or
             malabsorption syndrome.

          -  Has known central nervous system (CNS) metastases and/or carcinomatous meningitis that
             is either symptomatic or untreated.

          -  Any prior or current clinically significant ascites as measured by physical
             examination and that requires active paracentesis for control.

          -  Significant history of cardiac disease within 6 months prior to Day 1 of Cycle 1,
             myocardial infarction within the previous year, or current cardiac ventricular
             arrhythmias requiring medication.

          -  History or evidence of poorly controlled arterial hypertension.

          -  Any serious or uncontrolled medical disorder or active infection may increase the risk
             associated with study participation or dose.

          -  Administration of drugs known as strong CYP3A4 inducers or strong CYP3A4 inhibitors
             and the last dose was given in &lt; 5 half-lives from the first investigational product
             administration.

        Other inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wendie Yuan</last_name>
    <phone>+86 21 61097678</phone>
    <email>cstonera@cstonepharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ashford Cancer Centre Research</name>
      <address>
        <city>Kurralta Park</city>
        <state>South Australia</state>
        <zip>5037</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 13, 2019</study_first_submitted>
  <study_first_submitted_qc>December 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2019</study_first_posted>
  <last_update_submitted>January 17, 2020</last_update_submitted>
  <last_update_submitted_qc>January 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

